Summit Global Investments bought a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 38,800 shares of the medical instruments supplier’s stock, valued at approximately $639,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. boosted its position in OraSure Technologies by 10.6% during the second quarter. BlackRock Inc. now owns 8,480,830 shares of the medical instruments supplier’s stock worth $139,679,000 after acquiring an additional 810,442 shares during the last quarter. Fred Alger Management Inc. boosted its position in OraSure Technologies by 62.8% during the second quarter. Fred Alger Management Inc. now owns 2,695,239 shares of the medical instruments supplier’s stock worth $44,391,000 after acquiring an additional 1,040,166 shares during the last quarter. Peregrine Capital Management LLC boosted its position in OraSure Technologies by 10.0% during the second quarter. Peregrine Capital Management LLC now owns 1,047,193 shares of the medical instruments supplier’s stock worth $17,247,000 after acquiring an additional 95,559 shares during the last quarter. Emerald Advisers Inc. PA boosted its position in OraSure Technologies by 49.1% during the second quarter. Emerald Advisers Inc. PA now owns 1,007,294 shares of the medical instruments supplier’s stock worth $16,590,000 after acquiring an additional 331,922 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust boosted its position in OraSure Technologies by 52.7% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 836,396 shares of the medical instruments supplier’s stock worth $13,775,000 after acquiring an additional 288,653 shares during the last quarter. Hedge funds and other institutional investors own 92.25% of the company’s stock.

A number of analysts recently issued reports on OSUR shares. TheStreet upgraded shares of OraSure Technologies from a “c+” rating to a “b” rating in a research report on Thursday, August 9th. ValuEngine upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Stephens lowered shares of OraSure Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, July 16th. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Finally, BidaskClub lowered shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $21.33.

In other OraSure Technologies news, Director Charles W. Patrick sold 8,000 shares of OraSure Technologies stock in a transaction on Monday, August 27th. The shares were sold at an average price of $16.29, for a total value of $130,320.00. Following the transaction, the director now owns 54,298 shares in the company, valued at approximately $884,514.42. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.90% of the stock is owned by company insiders.

Shares of OSUR opened at $16.03 on Friday. The firm has a market capitalization of $994.07 million, a price-to-earnings ratio of 31.43, a P/E/G ratio of 4.00 and a beta of 1.56. OraSure Technologies, Inc. has a fifty-two week low of $12.86 and a fifty-two week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, August 8th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.03. The company had revenue of $43.60 million for the quarter, compared to analyst estimates of $42.24 million. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. OraSure Technologies’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $0.09 EPS. equities research analysts expect that OraSure Technologies, Inc. will post 0.33 earnings per share for the current year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.